

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated May 5, 2026 (the “**Prospectus**”) of Metis TechBio Co., Ltd. (劑泰科技(北京)股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any of the securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States or any other jurisdiction where such distribution is prohibited by law, nor is this announcement an offer for sale or solicitation to purchase or subscribe for securities in the United States or any other jurisdictions. The Offer Shares have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States and may not be offered, sold, pledged or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act), except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A in reliance on Rule 144A or another exemption from, or in a transaction not subject to, registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur.

In connection with the Global Offering, CLSA Limited, as the stabilizing manager (the “**Stabilizing Manager**”) (or any person acting for it), on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager (or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilizing Manager (or any person acting for it) and in what the Stabilizing Manager (or any person acting for it) reasonably regards as the best interest of our Company, (b) may be discontinued at any time, and (c) is required to be brought to an end within 30 days after the last day for lodging applications under the Hong Kong Public Offering (which is Sunday, June 7, 2026). Such stabilization action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that no stabilizing action can be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date, and is expected to expire on Sunday, June 7, 2026, the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong. Potential investors of the Offer Shares should note that the Joint Sponsors and the Sponsor-Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Wednesday, May 13, 2026).



Metis TechBio Co., Ltd.
剂泰科技(北京)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 201,229,000 H Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	: 40,246,000 H Shares (as adjusted after reallocation)
Number of International Offer Shares	: 160,983,000 H Shares (as adjusted after reallocation and subject to the Over-allotment Option)
Offer Price	: HK\$10.50 per H Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and Accounting and Financial Reporting Council transaction levy of 0.00015%
Nominal value	: RMB0.10 per H Share
Stock code	: 7666

Joint Sponsors



Overall Coordinators and Joint Global Coordinators



Joint Bookrunners and Joint Lead Managers



METIS TECHBIO CO., LTD.

劑泰科技(北京)股份有限公司

ANNOUNCEMENT OF ALLOTMENT RESULTS

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated May 5, 2026 (the “**Prospectus**”) issued by Metis TechBio Co., Ltd. (劑泰科技(北京)股份有限公司) (the “**Company**”).

SUMMARY

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

Company information

Stock code	7666
Stock short name	METIS TECHBIO-P
Dealings commencement date	13 May 2026*

* see note at the end of the announcement

Price Information

Offer Price	HK\$10.50
-------------	-----------

Offer Shares and Share Capital

Number of Offer Shares (before exercise of the Over-allotment Option)	201,229,000
Final Number of Offer Shares in Hong Kong Public Offering (after reallocation)	40,246,000
Final Number of Offer Shares in International Offering (after reallocation and before exercise of the Over-allotment Option)	160,983,000
Number of issued shares upon Listing (before exercise of the Over-allotment Option)	1,152,513,850

Over-allocation

No. of Offer Shares over-allocated	30,184,000
---	------------

Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through deferred delivery or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website.

Proceeds

Gross proceeds (Note)	HK\$2,112.9 million
Less: Estimated listing expenses payable based on Offer Price	HK\$(120.2) million
Net proceeds	HK\$1,992.7 million

Note: Gross proceeds refer to the amount to which the issuer is entitled receive. For details of the use of proceeds, please refer to the section headed "Future Plans and Use of Proceeds" of the Prospectus. The Company will adjust the allocation of the net proceeds from the exercise of the Over-allotment Option (if any) for the purposes as set out in the section headed "Future Plans and Use of Proceeds" of the Prospectus on a pro rata basis.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	383,309
No. of successful applications	65,740
Subscription level	6910.96 times
Claw-back triggered	Yes
No. of Offer Shares initially available under the Hong Kong Public Offering	10,061,500
No. of Offer Shares reallocated from the International Offering (claw-back)	30,184,500
Final no. of Offer Shares under the Hong Kong Public Offering (after reallocation)	40,246,000
% of Offer Shares under the Hong Kong Public Offering to the Global Offering	20%

Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors can refer to www.eipo.com.hk/eIPOAllotment to perform a search by identification number or www.eipo.com.hk/eIPOAllotment for the full list of allottees.

INTERNATIONAL OFFERING

No. of places	208
Subscription Level	33.86 times
No. of Offer Shares initially available under the International Offering	191,167,500
No. of Offer Shares reallocated to the Hong Kong Public Offering (claw-back)	30,184,500
Final no. of Offer Shares under the International Offering (after reallocation)	160,983,000
% of Offer Shares under the International Offering to the Global Offering	80%

*The Directors confirm that, to the best of their knowledge, information and belief, save for consent under paragraphs 1C(1) and 1C(2) of Appendix F1 to the Listing Rules and Chapter 2.5 and Chapter 4.15 of the Stock Exchange's Guide for New Listing Applicants (the "**Placing Guidelines**") granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in the International Offering to existing Shareholder, close associates of existing Shareholders and connected clients of the overall coordinator(s), any syndicate member(s) (other than the overall coordinator(s)) or any distributor(s) (other than syndicate member(s)) as a cornerstone investor and a placee, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, Single Largest Shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, Single Largest Shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.*

The placees in the International Offering include the following:

Cornerstone Investors

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued H Shares after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>Existing shareholders or their close associates</i>
BlackRock	37,304,500	18.54%	3.54%	3.24%	No
UBS AM Singapore	11,191,000	5.56%	1.06%	0.97%	No
China Venture Capital Innovation Investment Fund Co., Ltd.	7,460,500	3.71%	0.71%	0.65%	No
Mirae	5,968,500	2.97%	0.57%	0.52%	No
HHLRA	5,968,500	2.97%	0.57%	0.52%	No
Deerfield	3,730,000	1.85%	0.35%	0.32%	No
RTW Funds	3,730,000	1.85%	0.35%	0.32%	No
Arc Avenue	3,730,000	1.85%	0.35%	0.32%	No
Huadeng Technology	3,730,000	1.85%	0.35%	0.32%	No
Isometry Global	3,730,000	1.85%	0.35%	0.32%	No
GF Fund	3,730,000	1.85%	0.35%	0.32%	No
ICBCUBS Entities	3,730,000	1.85%	0.35%	0.32%	No
China AMC (HK)	3,730,000	1.85%	0.35%	0.32%	No
Fullgoal Fund	3,730,000	1.85%	0.35%	0.32%	No
Lake Bleu	2,984,000	1.48%	0.28%	0.26%	No
Sage Partners	2,984,000	1.48%	0.28%	0.26%	No
ICBC Wealth Management	1,492,000	0.74%	0.14%	0.13%	No
ORIX Asia AM	1,492,000	0.74%	0.14%	0.13%	No
Total	110,415,000	54.87%	10.49%	9.58 %	

Note:

1. For further details of the cornerstone investors, please refer to the section headed “Cornerstone Investors” of the Prospectus.

Allottees with Waivers/Consents Obtained

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued H Shares after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>Relationship</i>
<i>Allottees with waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules and consent under paragraph 1C(2) of the Placing Guidelines in relation to allocations to existing Shareholders and close associates of existing Shareholders^(Note 1)</i>					
<i>Placees</i>					
Martis Fund	3,730,500	1.85%	0.35%	0.32%	A placee, an existing shareholder and a close associate of an existing shareholder
Yael Capital Management Limited	4,477,000	2.22%	0.43%	0.39%	A placee and a close associate of an existing shareholder
Mr. Tse Eric S Y	746,500	0.37%	0.07%	0.06%	A placee and a close associate of an existing shareholder
China Life Franklin Asset Management Co., Limited	261,000	0.13%	0.02%	0.02%	A placee and a close associate of an existing shareholder
Subtotal	9,215,000	4.58%	0.88%	0.80%	

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued H Shares after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>Relationship</i>
Allottees with consent under paragraph 1C(1) of the Placing Guidelines and Chapter 4.15 of the Guide for New Listing Applicants in relation to allocations to connected clients^(Note2)					
China AMC (HK)	3,730,000	1.85%	0.35%	0.32%	Connected client as a cornerstone
CITIC Securities Asset Management Company Limited (“ CITIC Asset Management ”)	1,500	0.0007%	0.0001%	0.0001%	Connected client as a placee
CITIC Securities Asset Management (HK) Limited (“ CITIC Securities Asset ”)	1,500	0.0007%	0.0001%	0.0001%	Connected client as a placee
Harvest Global Investments Limited (“ Harvest ”)	12,000	0.006%	0.001%	0.001%	Connected client as a placee
DWS Investments Hong Kong Limited (“ DWS ”)	12,000	0.006%	0.001%	0.001%	Connected client as a placee
HSBC Global Asset Management (Hong Kong) Limited (“ HSBC AM ”)	373,000	0.19%	0.04%	0.03%	Connected client as a placee
CITIC Securities International Capital Management Limited (“ CSI ”)	2,348,500	1.17%	0.22%	0.20%	Connected client as a placee
Subtotal	6,478,500	3.22%	0.62%	0.56%	

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued H Shares after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>Relationship</i>
-----------------	--------------------------------------	--	---	--	---------------------

Notes:

1. See the section headed “Others/Additional Information — Placing to the existing shareholders and/or their close associates with a prior waiver under Rule 10.04 of the Listing Rules and consent under paragraph 1C(2) of the Placing Guidelines” in this announcement for further details.
2. See “Waivers — Consent in respect of the Proposed Subscription of the Offer Shares by Connected Client” of the Prospectus and the section headed “Others/Additional Information — Placing to connected clients with a prior consent under paragraph 1C(1) of the Placing Guidelines” in this announcement for further details.

LOCK-UP UNDERTAKINGS

Key Persons^(Note 1) (as Defined under Rule 18C.14 of the Listing Rules)

<i>Name</i>	<i>Capacity</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued Shares after the Global Offering upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings ^(Note 2)</i>
Dr. Lai	Co-founder, chairman of the Board, executive Director and chief executive officer	—	—	May 12, 2028
Scientia HK	Dr. Lai’s close associate	121,334,260	10.53%	May 12, 2028
Delos Holding	Dr. Lai’s close associate	16,000,000	1.39%	May 12, 2028
Dechi Holding	Dr. Lai’s close associate	10,232,590	0.89%	May 12, 2028
Dr. Chen	Co-founder, executive Director and chief research and development officer	66,913,490	5.81%	May 12, 2028
Dr. Wang	Co-founder, executive Director and chief operating officer	34,911,380	3.03%	May 12, 2028

<i>Name</i>	<i>Capacity</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued Shares after the Global Offering upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings ^(Note 2)</i>
Nanjing Chengtai Yuxin	Dr. Wang's close associate	25,857,170	2.24%	May 12, 2028
Hangzhou Shengtai	Dr. Wang's close associate	16,524,730	1.43%	May 12, 2028
Subtotal		291,773,620	25.32%	

Notes:

1. *Dr. Lai, Dr. Chen and Dr. Wang are our Co-founders, executive Directors and senior management, each being our key persons responsible for our technical operations and/or the research and development of our Specialist Technology Products, who are subject to lock-up requirements pursuant to Rule 18C.14 of the Listing Rules. In addition, our key persons for the purpose of Rule 18C.14 of the Listing Rules also include (i) Dr. Alan Fu, Dr. Wei Xu and Mr. Mark Robert Herbert, each being a senior management member of the Company, and (ii) Dr. Andong Liu, our vice president and head of technology and one of our key personnel responsible for our Company's technical operations and/or the research and development of our Specialist Technology Products (collectively, the “Other Key Persons”). As of the date of the Prospectus, the Other Key Persons held certain Equity Incentives under our Employee Incentive Schemes, for further details of the Employee Incentives, please refer to section headed “Appendix V — Statutory and General Information — Further Information about our Directors, Senior Management and Substantial Shareholders — 5. Employee Incentive Schemes.” in the Prospectus.*
2. *The lock-up period commences on the date by reference to which disclosure of its shareholding is made in the Prospectus and ends on the date which is 24 months from the Listing Date, i.e. May 12, 2028. In the event that upon the notification by the Stock Exchange that the Company will no longer be regarded as a Pre-Commercial Company after the Listing, the lock-up period will expire on the later of: (i) the date on which such lock-up periods would have ended if the Company had applied for listing as a Commercial Company; and (ii) the date falling on the 30th day after the announcement on the removal of designation as a Pre-Commercial Company as required under Rule 18C.24 of the Listing Rules.*

Pathfinder SIIIs

Name <small>Note 1</small>	Capacity	Number of Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued Shares after the Global Offering upon Listing (assuming the Over-allotment Option is not exercised)	Last day subject to the lock-up undertakings <small>(Note 1)</small>
CICC	Pathfinder SIIIs	108,800,000	9.44%	May 12, 2027
HSG	Pathfinder SIIIs	65,558,660	5.69%	May 12, 2027
Beijing PICC Health and Pension Industry Investment Fund (Limited Partnership) (北京人保健康養老產業投資基金(有限合夥)) (“PICC Health & Pension Fund”)	Pathfinder SIIIs	50,324,060	4.37%	May 12, 2027
5Y Capital	Pathfinder SIIIs	45,463,970	3.94%	May 12, 2027
Jiangsu Jiequan Chengda Equity Investment Centre (Limited Partnership) (江蘇捷泉成達股權投資中心(有限合夥))	Pathfinder SIIIs	35,025,550	3.04%	May 12, 2027

Note:

1. In accordance with Rule 18C.14 of the Listing Rules, the required lock-up period commences on the date by reference to which disclosure of its shareholding is made in the Prospectus and ends on the date which is 12 months from the Listing Date, i.e. May 12, 2027. In the event that upon the notification by the Stock Exchange that the Company will no longer be regarded as a Pre-Commercial Company after the Listing, the lock-up period will expire on the later of: (i) the date on which such lock-up periods would have ended if the Company had applied for listing as a Commercial Company; and (ii) the date falling on the 30th day after the announcement on the removal of designation as a Pre-Commercial Company as required under Rule 18C.24 of the Listing Rules.

Single Largest Shareholders

Name <i>Note 1</i>	Capacity	Number of Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued Shares after the Global Offering upon Listing (assuming the Over-allotment Option is not exercised)	Last day subject to the lock-up undertakings <i>(Note 1)</i>
Dr. Wang	Beneficial Interest	34,911,380	3.03%	May 12, 2028
Dr. Chen	Beneficial Interest	66,913,490	5.81%	May 12, 2028
Dr. Lai/Scientia HK <i>(Note 2)</i>	Beneficial Interest	121,334,260	10.53%	May 12, 2028
Delos <i>(Note 3)</i>	Beneficial Interest	16,000,000	1.39%	May 12, 2028
Nanjing Chengtai Yuxin	Beneficial Interest	25,857,170	2.24%	May 12, 2028
Hangzhou Shengtai	Beneficial Interest	16,524,730	1.43%	May 12, 2028
Dechi Holding <i>(Note 4)</i>	Beneficial Interest	10,232,590	0.89%	May 12, 2028

Notes:

1. The lock-up period commences on the date by reference to which disclosure of its shareholding is made in the Prospectus and ends on the date which is 24 months from the Listing Date, i.e. May 12, 2028. In the event that upon the notification by the Stock Exchange that the Company will no longer be regarded as a Pre-Commercial Company after the Listing, the lock-up period will expire on the later of: (i) the date on which such lock-up periods would have ended if the Company had applied for listing as a Commercial Company; and (ii) the date falling on the 30th day after the announcement on the removal of designation as a Pre-Commercial Company as required under Rule 18C.24 of the Listing Rules.
2. Scientia HK Limited, a private company limited by shares incorporated on February 17, 2023, which is wholly owned by Dr. Lai.
3. As of the date of this announcement, Delos Holding was controlled by Dr. Lai as to approximately 38.57% and the remaining 61.43% equity interests were held by the relevant grantees under the 2023 Equity Incentive Plan, none of whom holds 30% or more of the equity interests therein.
4. As of the date of this announcement, Dechi Holding was owned as to (i) 3.91% by Dr. Lai; (ii) 44.82% by Dr. Alan Fu; (iii) 34.04% by Mr. Mark Robert Herbert; and (iv) 17.23% by three consultants of our Company. Dr. Lai controlled Dechi Holding through the only one management share he held and he is also responsible for the day-to-day decision making of Dechi Holding.

Existing Shareholders

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued Shares after the Global Offering upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued H shares after the Global Offering upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i>
Dr. Wang	34,911,380	24,437,966	3.03%	2.32%	May 12, 2028
Dr. Chen	66,913,490	46,839,443	5.81%	4.45%	May 12, 2028
Dr. Lai/Scientia HK ^(Note 1)	121,334,260	84,933,982	10.53%	8.07%	May 12, 2028
Delos ^(Note 2)	16,000,000	16,000,000	1.39%	1.52%	May 12, 2028
Nanjing Chengtai Yuxin	25,857,170	25,857,170	2.24%	2.46%	May 12, 2028
Hangzhou Shengtai	16,524,730	16,524,730	1.43%	1.57%	May 12, 2028
Dechi Holding ^(Note 3)	10,232,590	10,232,590	0.89%	0.97%	May 12, 2028
Beijing Yuhetai	985,000	985,000	0.09%	0.09%	May 12, 2027
CICC Kangrui	72,533,330	50,773,331	6.29%	4.82%	May 12, 2027
PICC Health & Pension Fund	50,324,060	50,324,060	4.37%	4.78%	May 12, 2027
Evolution Holding	31,916,730	31,916,730	2.77%	3.03%	May 12, 2027
HSG Seed I	43,420,100	43,420,100	3.77%	4.12%	May 12, 2027
LS Metis	43,225,210	43,225,210	3.75%	4.11%	May 12, 2027
Martis Fund	42,616,430	42,616,430	3.70%	4.05%	May 12, 2027
XtalPi	32,146,460	32,146,460	2.79%	3.05%	May 12, 2027
CICC Healthcare	36,266,670	25,386,669	3.15%	2.41%	May 12, 2027
Jiequan Chengda	35,025,550	35,025,550	3.04%	3.33%	May 12, 2027
Matrice Capital	30,620,100	30,620,100	2.66%	2.91%	May 12, 2027
Duckling Fund	29,771,710	29,771,710	2.58%	2.83%	May 12, 2027
FreeS	27,235,920	27,235,920	2.36%	2.59%	May 12, 2027

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued Shares after the Global Offering upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued H shares after the Global Offering upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i>
HSG Venture VIII	22,138,560	22,138,560	1.92%	2.10%	May 12, 2027
Guangzhou CMB	16,251,850	16,251,850	1.41%	1.54%	May 12, 2027
Vibrant Evolution	13,547,240	13,547,240	1.18%	1.29%	May 12, 2027
IMO Global	6,094,450	6,094,450	0.53%	0.58%	May 12, 2027
Chia Tai Pharmaceutical Group Investment Co., Limited	8,051,850	8,051,850	0.70%	0.76%	May 12, 2027
Kunshan Fengrui	7,734,860	7,734,860	0.67%	0.73%	May 12, 2027
YUAN BEN CHEN XING	7,236,680	7,236,680	0.63%	0.69%	May 12, 2027
Monolith	6,773,620	6,773,620	0.59%	0.64%	May 12, 2027
Chengdu Fengrui	5,366,960	5,366,960	0.47%	0.51%	May 12, 2027
Tianjin Taixi	4,064,170	4,064,170	0.35%	0.39%	May 12, 2027
Yael Capital	2,616,850	2,616,850	0.23%	0.25%	May 12, 2027
Taiping GBA	2,417,780	2,417,780	0.21%	0.23%	May 12, 2027
Yael Evergreen	2,415,560	2,415,560	0.21%	0.23%	May 12, 2027
Nanjing CMB	1,260,920	1,260,920	0.11%	0.12%	May 12, 2027
Shanghai Ziyuan	875,640	875,640	0.08%	0.08%	May 12, 2027
Alaya Capital Partners Limited	25,155,100	25,155,100	2.18%	2.39%	May 12, 2027
Beijing Medical and Health	25,734,780	25,734,780	2.23%	2.44%	May 12, 2027
Beijing Daxing	19,301,080	19,301,080	1.67%	1.83%	May 12, 2027
AHI Investment	6,386,010	6,386,010	0.55%	0.61%	May 12, 2027

Notes:

- Scientia HK Limited, a private company limited by shares incorporated on February 17, 2023, which is wholly owned by Dr. Lai.*
- As of the date of this announcement, Delos Holding was controlled by Dr. Lai as to approximately 38.57% and the remaining 61.43% equity interests were held by the relevant grantees under the 2023 Equity Incentive Plan, none of whom holds 30% or more of the equity interests therein.*
- As of the date of this announcement, Dechi Holding was owned as to (i) 3.91% by Dr. Lai; (ii) 44.82% by Dr. Alan Fu; (iii) 34.04% by Mr. Mark Robert Herbert; and (iv) 17.23% by three consultants of our Company. Dr. Lai controlled Dechi Holding through the only one management share he held and he is also responsible for the day-to-day decision making of Dechi Holding.*

Cornerstone Investors

Name	Number of Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued Shares after the Global Offering upon Listing (assuming the Over-allotment Option is not exercised)	Last day subject to the lock-up undertakings ^(Note 1)
BlackRock	37,304,500	3.24%	November 12, 2026
UBS AM Singapore	11,191,000	0.97%	November 12, 2026
China Venture Capital Innovation Investment Fund Co., Ltd.	7,460,500	0.65%	November 12, 2026
Mirae	5,968,500	0.52%	November 12, 2026
HHLRA	5,968,500	0.52%	November 12, 2026
Deerfield	3,730,000	0.32%	November 12, 2026
RTW Funds	3,730,000	0.32%	November 12, 2026
Arc Avenue	3,730,000	0.32%	November 12, 2026
Huadeng Technology	3,730,000	0.32%	November 12, 2026
Isometry Global	3,730,000	0.32%	November 12, 2026
GF Fund	3,730,000	0.32%	November 12, 2026
ICBCUBS Entities	3,730,000	0.32%	November 12, 2026
China AMC (HK)	3,730,000	0.32%	November 12, 2026
Fullgoal Fund	3,730,000	0.32%	November 12, 2026
Lake Bleu	2,984,000	0.26%	November 12, 2026
Sage Partners	2,984,000	0.26%	November 12, 2026
ICBC Wealth Management	1,492,000	0.13%	November 12, 2026
ORIX Asia AM	1,492,000	0.13%	November 12, 2026
<p><i>Note:</i></p> <p>1. In accordance with the relevant cornerstone investment agreements, the required lock-up periods will end on November 12, 2026. The Cornerstone Investors will cease to be prohibited from disposing of or transferring the H Shares subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date.</p>			

PLACEE CONCENTRATION ANALYSIS

Placees	Number of H Shares allotted	Allotment as % of International Offering (assuming the Over-allotment Option is not exercised)	Allotment as % of International Offering (assuming the Over-allotment Option is fully exercised)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is not exercised)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is fully exercised)	Number of Shares held upon Listing	% of total issued share capital upon Listing (assuming the Over-allotment Option is not exercised)	% of total issued share capital upon Listing (assuming the Over-allotment Option is fully exercised)
Top 1	37,304,500	23.17%	19.51%	18.54%	16.12%	37,304,500	3.24%	3.15%
Top 5	67,893,000	42.17%	35.52%	33.74%	29.34%	67,893,000	5.89%	5.74%
Top 10	89,157,000	55.38%	46.64%	44.31%	38.53%	166,577,550	14.45%	14.08%
Top 25	136,903,500	85.04%	71.61%	68.03%	59.16%	214,324,050	18.60%	18.12%

Note

* Ranking of placees is based on the number of H Shares allotted to the placees.

H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders	Number of H Shares allotted	Allotment as % of International Offering (assuming the Over-allotment Option is not exercised)	Allotment as % of International Offering (assuming the Over-allotment Option is fully exercised)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is not exercised)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is fully exercised)	Number of H Shares held upon Listing	% of total issued H share capital upon Listing (assuming the Over-allotment Option is not exercised)	% of total issued H share capital upon Listing (assuming the Over-allotment Option is fully exercised)	% of total issued share capital upon Listing (assuming the Over-allotment Option is not exercised)	% of total issued share capital upon Listing (assuming the Over-allotment Option is fully exercised)
Top 1	0	0.00%	0.00%	0.00%	0.00%	224,825,881	21.35%	20.76%	19.51%	19.01%
Top 5	3,730,500	2.32%	1.95%	1.85%	1.61%	492,987,241	46.82%	45.52%	42.77%	41.68%
Top 10	41,035,000	25.49%	21.47%	20.39%	17.73%	705,230,161	66.98%	65.11%	61.19%	59.63%
Top 25	77,108,000	47.90%	40.34%	38.32%	33.32%	921,338,161	87.50%	85.06%	79.94%	77.90%

Note

* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders	Allotment as % of International Offering (assuming the Over-allotment Option is not exercised)					Number of H Shares held upon Listing	% of total issued share capital upon Listing (assuming the Over-allotment Option is not exercised)		Number of H Shares held upon Listing	% of total issued share capital upon Listing (assuming the Over-allotment Option is fully exercised)	
	Number of H Shares allotted	Over-allotment Option is not exercised)	Over-allotment Option is fully exercised)	Over-allotment Option is not exercised)	Over-allotment Option is fully exercised)		Number of Shares held upon Listing	Over-allotment Option is not exercised)		Number of Shares held upon Listing	Over-allotment Option is fully exercised)
Top 1	0	0.00%	0.00%	0.00%	0.00%	224,825,881	291,773,620	25.32%		24.67%	
Top 5	3,730,500	2.32%	1.95%	1.85%	1.61%	492,987,241	592,574,980	51.42%		50.10%	
Top 10	41,035,000	25.49%	21.47%	20.39%	17.73%	705,230,161	804,817,900	69.83%		68.05%	
Top 25	77,108,000	47.90%	40.34%	38.32%	33.32%	921,338,161	1,020,925,900	88.58%		86.32%	

Note

* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

METIS TECHBIO CO., LTD.

FINAL

BASIS OF ALLOTMENT FOR PRESS ANNOUNCEMENT

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
POOL A			
500	93,334	132 out of 93,334 to receive 500 Shares	0.14%
1,000	18,254	52 out of 18,254 to receive 500 Shares	0.14%
1,500	10,141	43 out of 10,141 to receive 500 Shares	0.14%
2,000	19,104	108 out of 19,104 to receive 500 Shares	0.14%
2,500	9,301	66 out of 9,301 to receive 500 Shares	0.14%
3,000	7,928	67 out of 7,928 to receive 500 Shares	0.14%
3,500	3,341	33 out of 3,341 to receive 500 Shares	0.14%
4,000	4,849	55 out of 4,849 to receive 500 Shares	0.14%
4,500	7,406	94 out of 7,406 to receive 500 Shares	0.14%
5,000	11,684	165 out of 11,684 to receive 500 Shares	0.14%
6,000	4,628	79 out of 4,628 to receive 500 Shares	0.14%
7,000	4,081	81 out of 4,081 to receive 500 Shares	0.14%
8,000	8,387	190 out of 8,387 to receive 500 Shares	0.14%
9,000	8,546	218 out of 8,546 to receive 500 Shares	0.14%
10,000	14,292	405 out of 14,292 to receive 500 Shares	0.14%
15,000	10,263	436 out of 10,263 to receive 500 Shares	0.14%
20,000	8,514	482 out of 8,514 to receive 500 Shares	0.14%
25,000	6,592	466 out of 6,592 to receive 500 Shares	0.14%
30,000	5,475	465 out of 5,475 to receive 500 Shares	0.14%
35,000	3,934	390 out of 3,934 to receive 500 Shares	0.14%
40,000	3,937	446 out of 3,937 to receive 500 Shares	0.14%
45,000	3,223	411 out of 3,223 to receive 500 Shares	0.14%
50,000	7,194	1,018 out of 7,194 to receive 500 Shares	0.14%
60,000	4,694	797 out of 4,694 to receive 500 Shares	0.14%
70,000	3,578	709 out of 3,578 to receive 500 Shares	0.14%
80,000	4,111	931 out of 4,111 to receive 500 Shares	0.14%
90,000	3,663	933 out of 3,663 to receive 500 Shares	0.14%
100,000	18,906	5,351 out of 18,906 to receive 500 Shares	0.14%
200,000	12,147	6,876 out of 12,147 to receive 500 Shares	0.14%
300,000	8,069	6,852 out of 8,069 to receive 500 Shares	0.14%
400,000	10,507	500 Shares plus 1,388 out of 10,507 to receive additional 500 Shares	0.14%
	<u>340,083</u>	Total number of Pool A successful applicants: 38,858	

METIS TECHBIO CO., LTD.**FINAL****BASIS OF ALLOTMENT FOR PRESS ANNOUNCEMENT**

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT POOL B	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
500,000	22,231	8,087 out of 22,231 to receive 500 Shares	0.04%
1,000,000	8,076	5,876 out of 8,076 to receive 500 Shares	0.04%
1,500,000	3,977	500 Shares plus 363 out of 3,977 to receive additional 500 Shares	0.04%
2,000,000	2,363	500 Shares plus 1,075 out of 2,363 to receive additional 500 Shares	0.04%
2,500,000	1,455	500 Shares plus 1,192 out of 1,455 to receive additional 500 Shares	0.04%
3,000,000	989	1,000 Shares plus 181 out of 989 to receive additional 500 Shares	0.04%
3,500,000	650	1,000 Shares plus 355 out of 650 to receive additional 500 Shares	0.04%
4,000,000	949	1,000 Shares plus 864 out of 949 to receive additional 500 Shares	0.04%
5,030,500	2,536	1,500 Shares plus 1,674 out of 2,536 to receive additional 500 Shares	0.04%
	<u>43,226</u>	Total number of Pool B successful applicants: 26,882	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the places or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

The Directors and the Overall Coordinators confirm that at least 50% of the total number of the Offer Shares have been allocated to and taken up by independent price setting investors in compliance with Rule 18C.08 of the Listing Rules.

The Directors further confirm that at least 25% of the issued share capital of the Company will be held by sophisticated independent investors at the time of Listing in compliance with Chapter 2.5 of the Guide for New Listing Applicants.

OTHERS/ADDITIONAL INFORMATION

Reallocation

As the Hong Kong Public Offering has been oversubscribed 50 times or more, the reallocation as described in the section headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation and Clawback” of the Prospectus has been applied. As a result of the above, the final number of Offer Shares under the Hong Kong Public Offering is adjusted to 40,246,000 Shares, representing approximately 20.00% of the total number of Offer Shares available under the Global Offering (assuming the Over-allotment Option is not exercised), and the final number of Offer Shares under the International Offering is adjusted to 160,983,000 Shares, representing approximately 80.00% of the total number of Offer Shares under the Global Offering (assuming the Over-allotment Option is not exercised).

Placing to the existing shareholders and/or their close associates with a prior waiver under Rule 10.04 of the Listing Rules and consent under paragraph 1C(2) of the Placing Guidelines

The Company has applied for a waiver under Rule 10.04 of the Listing Rules and a consent under paragraph 1C(2) of Appendix F1 to the Listing Rules, to permit the existing shareholders and/or its close associates to participate as placees in the Global Offering to subscribe for the Offer Shares to be issued by the Company under the International Offering (together, the “**Existing Shareholder Participants**”). The Stock Exchange has agreed to grant the requested waiver and consent subject to the conditions that:

- (a) the allocation to the Existing Shareholder Participants will not affect the Company’s ability to satisfy its public float requirement under Rule 8.08(1) (as amended and replaced by Rule 19A.13A) and 18C.08 of the Listing Rules;
- (b) the Company and the Joint Sponsors confirm that no preferential treatment has been, nor will be directly or indirectly, given to the Existing Shareholder Participants as placees by virtue of their relationship with the Company in any allocation in the Global Offering, other than the preferential treatment of assured entitlement under the cornerstone investment at the Offer Price and the terms are substantially the same as other cornerstone investors; and
- (c) details of the subscription of the Offer Shares by the Existing Shareholder Participants as placees under the Global Offering are disclosed in this allotment results announcement of the Company.

For details of the allocations of Offer Shares to such Existing Shareholder Participants, please refer to the section headed “Allotment Results Details — International Offering — Allottees with Waivers/Consents Obtained” in this announcement.

Placing to connected clients with a prior consent under paragraph 1C(1) of the Placing Guidelines

Under the International Offering, certain Offer Shares were placed to connected clients of their connected distributors pursuant to the Placing Guidelines.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 1C(1) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to the connected clients. The allocation of Offer Shares to such connected clients is in compliance with all the conditions under the consent granted by the Stock Exchange. Details of the placement to connected clients are set out below:

No.	Connected Distributor	Connected Client	Relationship with the Connected Distributor	Identities of the ultimate beneficial owners of the Offer Shares	Whether the Connected Client is a collective investment scheme which is not authorised by the SFC or is expected to hold the Offer Shares on behalf of such scheme	Number of Offer Shares allocated to the connected client	Approximate percentage of total number of Offer Shares under the Global Offering (assuming no exercise of the Over-allotment Option)	Approximate percentage of total issued share capital after the Global Offering (assuming no exercise of the Over-allotment Option)
Part A — Connected Clients holding the beneficial interest of the Offer Shares on a discretionary basis on behalf of independent third parties								
1.	CLSA Limited (“CLSA”)	CITIC Securities Asset Management Company Limited (“CITIC Asset Management”)	CLSA and CITIC Asset Management, are members of the same group of companies.	Please refer to Note 1	Yes	1,500	0.0007%	0.0001%
2.	CLSA	CITIC Securities Asset Management (HK) Limited (“CITIC Securities Asset”)	CITIC Securities Asset is a member of the same group of companies as CLSA.	Please refer to Note 2	No	1,500	0.0007%	0.0001%

No.	Connected Distributor	Connected Client	Relationship with the Connected Distributor	Identities of the ultimate beneficial owners of the Offer Shares	Whether the Connected Client is a collective investment scheme which is not authorised by the SFC or is expected to hold the Offer Shares on behalf of such scheme	Number of Offer Shares allocated to the connected client	Approximate percentage of total number of Offer Shares under the Global Offering (assuming no exercise of the Over-allotment Option)	Approximate percentage of total issued share capital after the Global Offering (assuming no exercise of the Over-allotment Option)
Part A — Connected Clients holding the beneficial interest of the Offer Shares on a discretionary basis on behalf of independent third parties								
3.	Deutsche Bank AG, Hong Kong Branch (“DBHK”)	Harvest Global Investments Limited (“Harvest”)	Harvest is a wholly-owned subsidiary of Harvest Financial Group Limited, which in turn is wholly owned by Harvest Fund Management Co., Ltd. Harvest Fund Management Co., Ltd. is 30% owned by DWS Investments Singapore Limited. DWS Investments Singapore Limited is a wholly-owned subsidiary of DWS Group GmbH & Co. KGaA. DWS Group GmbH & Co. KGaA is partially owned by DB Beteiligungs-Holdings GmbH (79.49%), Nippon Life Insurance (5%) and outside shareholders (15.51 %) as at Dec 31, 2025. DB Beteiligungs-Holdings GmbH is wholly owned by Deutsche Bank AG.	Please refer to Note 3	No	12,000	0.006%	0.001%
4.	DBHK	DWS Investments Hong Kong Limited (“DWS”)	DWS is a wholly-owned subsidiary of DWS Group GmbH & Co. KGaA. DWS Group GmbH & Co. KGaA is partially owned by DB Beteiligungs-Holdings GmbH (79.49%), Nippon Life Insurance (5%) and outside shareholders (15.51%) as at December 31, 2025. DB Beteiligungs-Holdings GmbH is wholly owned by Deutsche Bank AG.	Please refer to Note 4	No	12,000	0.006%	0.001%

No.	Connected Distributor	Connected Client	Relationship with the Connected Distributor	Identities of the ultimate beneficial owners of the Offer Shares	Whether the Connected Client is a collective investment scheme which is not authorised by the SFC or is expected to hold the Offer Shares on behalf of such scheme	Number of Offer Shares allocated to the connected client	Approximate percentage of total number of Offer Shares under the Global Offering (assuming no exercise of the Over-allotment Option)	Approximate percentage of total issued share capital after the Global Offering (assuming no exercise of the Over-allotment Option)
Part A — Connected Clients holding the beneficial interest of the Offer Shares on a discretionary basis on behalf of independent third parties								
5.	The Hongkong And Shanghai Banking Corporation Limited (“HSBC”)	HSBC Global Asset Management (Hong Kong) Limited (“HSBC AM”)	HSBC AM is a fellow subsidiary of HSBC.	Please refer to Note 5	No	373,000	0.19%	0.03%

Notes:

- CITIC Asset Management will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds on behalf of their investors, each of which is an independent third party.*

The funds are as follows: (i) CITIC SECURITIES COMPANY LIMITED-XINHANG ZHIYUAN NO.3(中信証券信航致遠 3 號集合資產管理計劃), and (ii) CITIC Securities AM-Guibinfengyuan No.118 QDII(中信証券資管貴賓豐元 118 號 QDII 集合資產管理計劃).

None of the CITIC Asset Management Ultimate Clients holds more than 30% ultimate beneficial interest in the aforementioned funds, and all of them with discretionary management.

- CITIC Securities Asset will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds on behalf of their investors, each of which is an independent third party.*

The funds is as follows: CITIC Securities Asset Management (HK) Limited – CLSA CT Limited Sub Account 26. Invested 100% by Roofer Securities Limited, of which UBO holding 30% or more interest is natural person Karen Liu.

3. *Harvest will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds on behalf of their investors, each of which is an independent third party.*

The funds are as follows: (i) HARVEST ESG CHINA A RESEARCH SELECT FUND, (ii) ASIA FRONTIER EQUITY FUND, (iii) Harvest BOCHK Diverse Income Fund, (iv) Harvest Total Return Fund, and (v) HGI IPO MANDATE NO.1.

No ultimate beneficial owner holds 30% or more interest in the funds.

4. *DWS will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds on behalf of their investors, each of which is an independent third party.*

The fund is as follows: DWS Invest Chinese Equities.

No ultimate beneficial owner holds 30% or more interest in the funds.

5. *HSBC AM will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds on behalf of their investors, each of which is an independent third party.*

The funds are as follows: (i) HSBC Global Investment Funds Asia Ex Japan Equity Smaller Companies, (ii) HSBC Global Investment Funds Chinese Equity, (iii) HSBC Global Investment Funds Hong Kong Equity, (iv) HSBC China Growth Fund, (v) HSBC China Momentum Fund, (vi) HSBC Collective Investment Trust – HSBC China Multi-Asset Income Fund, (vii) HSBC China Mother Fund, (viii) HSBC Pooled Investment Fund-HSBC Pooled Chinese Equity Fund, (ix) HSBC Pooled Investment Fund – HK HSBC Pooled Hong Kong Equity Fund, (x) HSBC Global RAIF Discretionary Asia Equity Next Generation Leaders Portfolio, (xi) HSBC Global RAIF – Discretionary Asia Equity Portfolio, and (xii) HSHK Asian Small Caps.

No ultimate beneficial owner holds 30% or more interest in the funds.

No.	Connected Distributor	Connected Client	Relationship with the Connected Distributor	Identities of the ultimate beneficial owners of the Offer Shares or, where applicable, details of the structured products under which the subscription by the Connected Client was made (e.g. OTC total return swaps)	Whether the Connected Client is a collective investment scheme which is not authorised by the SFC or is expected to hold the Offer Shares on behalf of such scheme	Number of Offer Shares allocated to the connected client	Approximate percentage of total number of Offer Shares under the Global Offering (assuming no exercise of the Over-allotment Option)	Approximate percentage of total issued share capital after the Global Offering (assuming no exercise of the Over-allotment Option)
Part B – Connected Client holding the beneficial interest of the Offer Shares on a non-discretionary basis on behalf of independent third parties								
1.	CLSA	CITIC Securities International Capital Management Limited (“CSI”)	CSI is a member of the same group of companies as CLSA.	Please refer to Note 1	No	2,348,500	1.17%	0.20%

Note:

1. *CSI will hold the Offer Shares as a placee under the International Offering on behalf of its ultimate clients (the “CSI Ultimate Clients”), on a non-discretionary basis, pursuant to which: (i) CSI will act as the single counterparty of the CSI Back-to-back TRS (the “CSI Back-to-back TRS”) to be entered into by it in connection with a total return swap order (the “CSI Client TRS”) placed and fully funded by the CSI Ultimate Clients, by which CSI will pass the full economic exposure of the Offer Shares placed to CSI to the CSI Ultimate Clients; (ii) as confirmed by CSI and CLSA, CSI will hold the legal title and beneficial interest in the Offer Shares, but will contractually agree to pass on the full economic exposure and return of the Offer Shares to the CSI Ultimate Clients, on a non-discretionary basis. The CSI Ultimate Clients may exercise their early termination rights to terminate the CSI Client TRS at any time from the trade date of the CSI Client TRS which should be on or after the date on which the Offer Shares are listed on the Stock Exchange; (iii) upon the final maturity or termination of the CSI Client TRS by the CSI Ultimate Clients, CSI will dispose of the Offer Shares on the secondary market and the CSI Ultimate Clients will receive a final termination amount of the CSI Back-to-back TRS which will have taken into account all the economic returns or economic loss in relation to the Offer Shares and the fixed amount of transaction fees of the CSI Back-to-back TRS and the CSI Client TRS. Due to its internal policy, CSI will not exercise the voting right of the Offer Shares during the terms of the CSI Back-to-back TRS; and (iv) CSI is not a collective investment scheme which is not authorized by the SFC, nor is expected to hold the Offer Shares on behalf of such scheme.*

The details of the CSI Ultimate Clients are as follows:

Name (CSI Ultimate Client)	Asset Manager	UBO of Asset Manager	UBO of CSI Ultimate Client
Panjing Wenheng Private Securities Investment Fund (盤京聞恒私募證券投資基金)	Shanghai Panjing Investment Management Center (Limited Partnership) (上海盤京投資管理中心(有限合夥))	Zhuang Tao (莊濤)	None
Panjing Wenheng Phase 2 Private Securities Investment Fund (盤京聞恒 2 期私募證券投資基金)	Shanghai Panjing Investment Management Center (Limited Partnership) (上海盤京投資管理中心(有限合夥))	Zhuang Tao (莊濤)	None
Lingding No.3 Private Securities Investment Fund (凌頂三號私募證券投資基金)	Ningbo Meishan Bonded Port Area Lingding Investment Management Co., Ltd. (寧波梅山保稅港區凌頂投資管理有限公司)	Chen Youfang (陳有方), Deng Chunyan (鄧春燕)	Xiong Nawei (熊納微)
Yuanle Qiangye Private Securities Investment Fund (源樂晟強業私募證券投資基金)	Xizang Yuanle Asset Management Co., Ltd. (西藏源樂晟資產管理有限公司)	Zeng Xiaojie (曾曉潔)	Hu Caiyang (胡彩陽)
Canaan China Flagship Fund	Not applicable	Not applicable	Liang Hao
Hover4pi Fund I OFC	Hover4pi Capital Management	He Hui	None
Global Multi Alpha Fund SP	Beevest Capital Management Limited	Zeng Shuzhen	Zeng Shuzhen
Gaoyi Qingrui No.6 Ruixing Fund (高毅慶瑞 6 號瑞行基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None
Gaoyi Liwei Jingxuan Weishi Fund (高毅利偉精選唯實基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None
Gaoyi Renhao Long-term Value Langrun Private Securities Investment Fund (高毅任昊長期價值朗潤私募證券投資基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None
Jintaiyang Gaoyi Guolu No.1 Chongyuan Fund (金太陽高毅國鸞 1 號崇遠基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None
Gaoyi Liwei Xinshi Private Fund (高毅利偉信實私募基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None
Gaoyi Guolu Xinyuan Private Securities Investment Fund (高毅國鸞信遠私募證券投資基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None

Name (CSI Ultimate Client)	Asset Manager	UBO of Asset Manager	UBO of CSI Ultimate Client
Gaoyi Renhao Youxuan Zhifu Private Securities Investment Fund (高毅任昊優選致福私募證券投資基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None
Gaoyi Qingrui Youxuan Ruize Private Securities Investment Fund (高毅慶瑞優選瑞澤私募證券投資基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None
Gaoyi Qingrui Zhenxuan Fengyuan Private Securities Investment Fund (高毅慶瑞臻選豐源私募證券投資基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None
Gaoyi Renhao Jingxuan Chengze Private Securities Investment Fund (高毅任昊精選承澤私募證券投資基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None
Gaoyi Renhao Zhenxuan Chunhe Private Securities Investment Fund (高毅任昊臻選春和私募證券投資基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None
Gaoyi Qingrui Jingxuan Ruixiang Convertible Bond Multi-Strategy Private Fund (高毅慶瑞精選瑞祥可轉債多策略私募基金)	Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥))	None	None
Evolution Darwin Shangshan No.3 Private Securities Investment Fund (進化論達爾文上善三號私募證券投資基金)	Hainan Evolution Asset Management Co., Ltd. (海南進化論私募基金管理有限公司)	Wang Yiping (王一平)	None

To the best of knowledge of CSI and having made all reasonable inquiries, each of the CSI Ultimate Clients and its UBOs is an independent third party of the Company, its subsidiaries, its substantial shareholders, CSI, CLSA and the companies which are members of the same group of companies as CLSA.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated May 5, 2026 issued by Metis TechBio Co., Ltd. (劑泰科技(北京)股份有限公司) for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.

- * *Potential investors of the Offer Shares should note that the Joint Sponsors and the Sponsor-Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters), may, in their sole and absolute discretion, upon giving notice in writing to the Company, terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on May 13, 2026).*

PUBLIC FLOAT AND FREE FLOAT

Pursuant to Rule 19A.13A of the Listing Rules, assuming that the Over-allotment Option is not exercised, based on the Offer Price of HK\$10.50 per Offer Share, the expected market capitalization of the Company upon the Listing is HK\$12,101.4 million, and the minimum prescribed public float percentage applicable to our Shares is 15%. Immediately after the completion of the Global Offering, 828,100,230 H Shares, representing approximately 71.85% of the issued share capital of our Company, will count towards the public float, thereby satisfying the minimum percentage requirement in compliance with Rule 19A.13A(1) of the Listing Rules.

Based on the Offer Price of HK\$10.50 per H Share, the Company satisfies the free float requirement under Rule 19A.13C(1)(b) of the Listing Rules.

The Directors confirm that, immediately following the completion of the Global Offering: (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company; (ii) there will not be any new substantial Shareholder (as defined in the Listing Rules) of the Company; (iii) the three largest public shareholders of the Company do not hold more than 50% of the H Shares in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Wednesday, May 13, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Wednesday, May 13, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Wednesday, May 13, 2026 (Hong Kong time). The H Shares will be traded in board lots of 500 H Shares each, and the stock code of the H Shares will be 7666.

By order of the Board
Metis TechBio Co., Ltd.
Tsai-Ta Lai

Chairman of the Board, executive Director and chief executive officer

Hong Kong, May 12, 2026

Directors of the Company named in the application to which this announcement relates are: (i) Dr. Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; (ii) Mr. Hantao Huang and Ms. Yuan Gong as non-executive Directors; and (iii) Mr. Frank Yee Chon Lyn, Dr. Jin Li and Dr. Peter Edward Lobie as proposed independent non-executive Directors.